Does TRT Cause Hair Loss? What the Evidence Shows

TRT can accelerate hair loss in genetically predisposed men via DHT conversion. Learn who is at risk, how the mechanism works, and what your options are.

Does TRT Cause Hair Loss?

Can testosterone replacement therapy cause hair loss? TRT can accelerate hair thinning in men who already carry a genetic predisposition to androgenetic alopecia (male-pattern baldness), but it does not create hair loss from scratch. The mechanism runs through a hormone called DHT, and whether you are vulnerable depends far more on your follicle genetics than on your testosterone dose. For men without that predisposition, the added risk appears minimal.

A few things worth keeping in mind at the outset:

• ▶Hair loss on TRT is driven by genetic sensitivity to DHT, not testosterone levels alone.
• ▶Men without androgenetic alopecia predisposition face little additional risk.
• ▶Several management options exist that do not require stopping therapy.
• ▶Low testosterone itself can contribute to hair thinning, so the relationship between hormones and hair runs in both directions.

Understanding exactly how DHT drives follicle miniaturization, and why only some men are vulnerable, starts with what is actually happening inside the hair follicle.

How Does DHT Actually Trigger Hair Loss?

DHT, short for dihydrotestosterone, is a more biologically potent form of testosterone. Your body converts testosterone into DHT using an enzyme called 5-alpha reductase, which sits inside skin and hair follicle tissue and acts like a chemical amplifier. DHT does not cause hair loss in every man; it only does so in follicles that carry a genetic sensitivity to it [1].

Here is what happens at the follicle level. DHT binds to androgen receptors inside the hair follicle, and in genetically sensitive follicles, that binding triggers a slow shrinking process called miniaturization. Think of each hair follicle as a flower pot: miniaturization gradually makes the pot smaller with each growth cycle, so the hair that regrows is finer and shorter than the previous one. Over many cycles, the pot becomes too small to support a visible hair at all [2].

Research published in the Journal of Dermatological Science in 2005 described a specific molecular chain reaction that explains this process clearly. DHT stimulates the synthesis of transforming growth factor-beta2 (TGF-beta2, a protein signal that tells hair follicle cells to stop dividing and begin dying) in dermal papilla cells, the specialized cells that anchor and feed each hair root [3]. Once TGF-beta2 rises, it suppresses epithelial cell proliferation and activates a programmed cell-death cascade. The result you would feel: hairs in affected zones grow back progressively thinner and shorter until they stop regrowing at all.

A study in the Journal of Clinical Endocrinology and Metabolism confirmed a related step: in dermal papilla cells taken from men with androgenetic alopecia, DHT actively suppressed Wnt-dependent keratinocyte (skin cell) growth, and this suppression was not seen in cells from men without the condition [4]. Wnt signaling is the pathway that tells hair follicle stem cells to enter the active growth phase. When DHT blocks it, the follicle stalls. In plain terms: DHT does not damage follicles in every man. It damages follicles that are genetically wired to shrink when DHT arrives.

Scalp follicles and body follicles carry different androgen receptor densities, which explains why DHT can thin scalp hair while simultaneously increasing body and facial hair [5]. The same hormone, opposite effects, different tissue programming.

Research using a DHT-treated mouse model found that DHT induced early hair regression, hair miniaturization, and density loss, and that these effects could be partly reversed by blocking the androgen receptor [6]. This animal evidence reinforces the central clinical point: it is the androgen receptor binding event, not DHT alone, that drives miniaturization.

Testosterone does not act in isolation, either. Its conversion into estradiol (the primary estrogen men also produce in small amounts) shapes the hormonal environment around the follicle. For a fuller look at that balance, the article on estradiol and testosterone in men walks through how these two hormones interact.

Does Starting TRT Meaningfully Raise DHT Levels?

For most men on injected testosterone, DHT rises modestly and tracks closely with how much free testosterone is available, the portion not bound to proteins in the blood. The increase is real, but it tends to stay within a physiologic range. What matters clinically is not just whether DHT rises, but whether your scalp follicles carry the receptor sensitivity to respond to that rise [1].

Delivery method makes a meaningful practical difference. Topical testosterone gels and creams, applied directly to the skin, tend to produce higher DHT elevations than injected testosterone at comparable doses. The skin contains high concentrations of 5-alpha reductase, so more conversion happens locally before the hormone reaches the bloodstream. Injectable testosterone bypasses that skin-based conversion step almost entirely.

The enzyme 5-alpha reductase exists in two functionally relevant forms (called type 1 and type 2 isoenzymes) with distinct anatomical distributions [7]. Type 2 is the dominant isoenzyme in scalp hair follicles and is the primary driver of DHT production in follicle tissue. This is why 5-alpha reductase inhibitors that preferentially target type 2 have been the mainstay pharmacological approach for androgenetic alopecia [8].

Several factors shape where your DHT lands on therapy:

Understanding how to read your hormone lab report helps here, because DHT is not always included in a standard panel and must be ordered separately. If DHT levels matter for your protocol, ask for it explicitly.

The choice of TRT delivery method is one of the most practical levers available, which raises the next question: who is actually at meaningful risk?

Who Is Actually at Risk for Hair Loss on TRT?

Most men on TRT will not notice meaningful hair loss. The men who do almost always had the genetic groundwork already laid before their first injection.

The Role of Genetics

Androgenetic alopecia is driven by how sensitive your hair follicles are to DHT, not just how much DHT is circulating. That sensitivity is largely inherited. Men with a strong family history of hair loss carry androgen receptor variants, small differences in the gene that controls how aggressively follicles respond to DHT [9]. Raising DHT through TRT can accelerate a process already written into your biology. It typically will not create a new problem where none existed.

The pattern matters too. Vertex thinning (crown recession) and temple thinning together follow the Norwood scale, a visual map of male-pattern hair loss that progresses from slight temple recession at Stage 1 toward more extensive loss at higher stages. Men already showing Norwood Stage 2 or above before TRT are the ones most likely to notice acceleration.

Research on androgenetic alopecia notes that in men with the condition, 5-alpha reductase activity in frontal and vertex scalp regions is elevated relative to occipital (back-of-head) regions, where androgen receptors are less densely expressed [10]. This anatomical gradient explains the characteristic pattern of loss and why the same circulating DHT level affects different scalp zones differently.

Wnt signaling inhibitors such as DKK1 (a protein that blocks hair follicle stem cell activation) are upregulated by DHT in genetically susceptible dermal papilla cells [11]. Early research into targeting these Wnt pathway inhibitors represents one of the more promising directions in androgenetic alopecia biology, though clinical-stage compounds are still under investigation.

A Practical Risk Table

Understanding your tier shapes the conversation with your prescribing clinician, and it also affects which age you might consider starting TRT if hair preservation is a priority.

What Are the Practical Options If Hair Matters to You?

If hair preservation matters, you have real levers to pull. None of them require abandoning TRT. The conversation with your clinician comes down to three areas: whether to add a DHT-reducing medication, whether to adjust your delivery method, and how to monitor what is actually changing.

5-Alpha Reductase Inhibitors on TRT

Finasteride blocks the type 2 isoenzyme of 5-alpha reductase, reducing DHT production in scalp tissue. It has regulatory approval for male-pattern hair loss and benign prostatic hyperplasia [8]. Less DHT means a weaker signal reaching the follicle. In clinical practice, some men on TRT add low-dose finasteride specifically to blunt the DHT rise that can accompany therapy.

Dutasteride inhibits both type 1 and type 2 isoenzymes of 5-alpha reductase, producing a more complete reduction in DHT than finasteride. Multiple randomized, double-blind, placebo-controlled trials have demonstrated its effectiveness in androgenetic alopecia, and in several comparative studies dutasteride showed greater efficacy than finasteride with a comparable side-effect profile [12]. The practical trade-off for either agent: reduced libido and mood changes occur in a subset of men, and that conversation belongs with your prescribing clinician rather than a supplement label.

Minoxidil, applied topically to the scalp, works through a different mechanism entirely. It extends the active growth phase of the hair cycle by widening blood vessels near the follicle. It does not affect DHT, so it pairs well with a 5-alpha reductase inhibitor for men who want both lines of defense.

Delivery Method Adjustments

Topical testosterone formulations applied to the skin tend to produce higher DHT levels relative to injected forms, because the skin contains significant 5-alpha reductase activity. Injections, including the subcutaneous approach covered in the TRT injection guide, often result in a more favorable testosterone-to-DHT ratio for men already concerned about follicle sensitivity.

Monitoring What Matters

Tracking serum DHT alongside standard labs gives your clinician an objective signal rather than a guess. If DHT climbs disproportionately, the protocol can be adjusted before significant shedding begins. For men also managing blood viscosity, the same principle of proactive monitoring applies, as detailed in the article on TRT and high hematocrit. Getting the big dials tuned first (testosterone, sleep, body composition) and then refining the smaller details like DHT management is how a well-run protocol stays responsive to the individual.

Common Questions About TRT and Hair

Will my hair grow back if I stop TRT? Miniaturized follicles that have been inactive for a long time are unlikely to fully recover on their own. Stopping TRT removes the additional DHT burden, which may slow further progression, but recovery of already lost hair is not reliably achieved without additional treatment.

Does testosterone dose determine hair loss risk? Dose matters insofar as higher doses provide more substrate for DHT conversion. However, follicle sensitivity, determined by genetics and androgen receptor density, is the more decisive variable. A man with low follicle sensitivity at a high dose may lose less hair than a man with high follicle sensitivity at a moderate dose.

Can I check my risk before starting? A baseline DHT measurement, a review of family history, and a scalp assessment by your clinician before therapy begins gives you the clearest picture of your individual risk tier.

What to Discuss With Your Clinician Before Starting TRT

A candid, well-prepared conversation before your first dose is where a personalized protocol either holds together or falls apart. Bring your full picture, not just a symptom list.

In clinical practice, the most useful pre-treatment disclosures and questions center on a few key areas:

• ▶Family hair loss history. Let your clinician know which relatives lost hair, at what age, and how fast. Pattern and timing tell a physician a great deal about your likely androgen sensitivity.
• ▶DHT baseline. Ask whether your lab panel will include a pre-treatment DHT reading. That number becomes your personal reference point if shedding starts later.
• ▶Scalp sensitivity symptoms. Any current thinning, increased shedding after showers, or a receding hairline at the temples deserves mention before you start, not after.
• ▶Delivery method preference. Topical formulations drive higher DHT than injections in many patients. If hair preservation matters to you, say so before a method is chosen.
• ▶Medications and supplements already on board. Finasteride, dutasteride, saw palmetto, and certain vitamins all interact with androgen metabolism and need to be on your clinician's radar.

A physician-supervised approach means the protocol responds to your labs and your lived experience together. For a broader look at what to expect from the evaluation process, hormone therapy for men: benefits, side effects, and how it works walks through the full clinical picture. If you are ready to start that conversation, reach out to schedule a consultation.

MORE FROM THE JOURNAL